Trial Profile
Two year longitudinal study comparing analysis of natalizumab versus fingolimod by including cortical lesions into No Evidence of Disease Activity (NEDA-3) concept
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Oct 2018
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary) ; Fingolimod
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 30 Oct 2018 New trial record
- 12 Oct 2018 Results presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis